logo-loader
RNS
viewSynairgen PLC

Synairgen plc - Grant of Options

RNS Number : 4363Q
Synairgen plc
19 June 2020
 

Press Release

Synairgen plc

('Synairgen' or the 'Company')

 

Grant of options

 

Southampton, UK - 19 June 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 18 June 2020 the Board of Synairgen granted options ('Options') over 1,767,985 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share.  The Options represent in aggregate 1.18 per cent. of the Company's issued share capital. 

 

The Options are issued under the Company's existing Long Term Incentive Plan and are exercisable between 18 June 2023 and 17 June 2030, subject to achievement of performance criteria related to the increase in the total shareholder return of the Company. Following this grant, Synairgen has 10,255,500 options in issue, representing 6.86 per cent. of the Company's issued share capital.

 

Included in the number of Options granted on 18 June 2020, the following Options were issued to directors:

 

Director

Options Issued

Richard Marsden

490,817

Dr. Phillip Monk

354,483

John Ward

381,749

 

Following the issue of the Options, the interests of the directors of the Company at

18 June 2020 are as follows:

 

Director

Total options

Ordinary shares

Total interest

Percentage holding of fully diluted share capital

Richard Marsden

3,533,839

367,825

3,901,664

2.44%

Dr. Phillip Monk

1,948,582

244,600

2,193,182

1.37%

John Ward

2,481,064

367,577

2,848,641

1.78%

Simon Shaw

-

1,531,239

1,531,239

0.96%

Iain Buchanan

212,765

112,741

325,506

0.20%

Dr. Bruce Campbell

-

322,830

322,830

0.20%

Prof. Stephen Holgate

-

886,931

886,931

0.56%

 

 

Jody Brookes and Victoria Tear, also persons disclosing managerial responsibilities, were granted 135,576 and 101,270 Options respectively.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')

 

For further information, please contact:

 

Synairgen plc 

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

 

finnCap

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

Tel: + 44 (0) 20 7220 0500

 

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

[email protected]

Tel: +44 (0) 20 3709 5700

 

Notes for Editors

 

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. 

 

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

 

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Richard Marsden

2.

Reason for notification

a)

Position / status

Chief Executive Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Synairgen LTIP

c)

Price(s) and volume(s)

 490,817 Options awarded

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 June 2020

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Dr Phillip Monk

2.

Reason for notification

a)

Position / status

Chief Scientific Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Synairgen LTIP

c)

Price(s) and volume(s)

 354,483 Options awarded

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 June 2020

f)

Place of the transaction

Outside a trading venue

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

John Ward

2.

Reason for notification

a)

Position / status

Finance Director

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Synairgen LTIP

c)

Price(s) and volume(s)

 381,749 Options awarded

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 June 2020

f)

Place of the transaction

Outside a trading venue

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Jody Brookes

2.

Reason for notification

a)

Position / status

Head of Clinical Operations

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Synairgen LTIP

c)

Price(s) and volume(s)

 135,576 Options awarded

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 June 2020

f)

Place of the transaction

Outside a trading venue

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Victoria Tear

2.

Reason for notification

a)

Position / status

Head of Laboratories

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Synairgen LTIP

c)

Price(s) and volume(s)

 101,270 Options awarded

 

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

18 June 2020

f)

Place of the transaction

Outside a trading venue

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEAPKPFSXEEFA

Quick facts: Synairgen PLC

Price: 218

Market: AIM
Market Cap: £325.76 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18